SANOFI news, videos and press releases
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
- Sanofi: Information concerning the total number of voting rights and shares - March 2024
- Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
- Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
- Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
- Sanofi: Information concerning the total number of voting rights and shares - January 2024
- Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
- Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
- Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
- Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
- Sanofi: Information concerning the total number of voting rights and shares - November 2023
- Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
- Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
- Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
- Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
- Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
- Sanofi: Information concerning the total number of voting rights and shares - October 2023
- Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
- Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
- Sanofi: Information concerning the total number of voting rights and shares - September 2023
- Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
- Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
- Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
- Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
- Sanofi: Information concerning the total number of voting rights and shares - July 2023
- Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
- Press release: Online availability of Sanofi’s half-year financial report for 2023
- Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
- Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
- Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
